Even though Ad-shRRM1 in itself showed potent inhibitory effects on cell proliferation, combination treatment with Ad-shRRM1 and GEM reduced the 50% inhibitory concentration (IC50) of GEM to a greater extent, in both of the RRM1 highly expressed bladder cancer cells. This evidence concerns the gene RRM1 and urinary bladder carcinoma.